"Picolog," a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo

Oncotarget

Volumn 3, Issue 1, 2012, Pages 58-66

  DeChristopher, Brian A ^a   Fan, Alice C ^b   Felsher, Dean W ^b   Wender, Paul A ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bryostatin; Lymphoma; Picolog; PKC

Indexed keywords

ANTINEOPLASTIC AGENT; BRYOSTATIN; PICOLOG;

ANIMAL; ARTICLE; BIOLOGICAL MODEL; CELL CULTURE; CELL GROWTH; CELL TRANSFORMATION; CHEMISTRY; DOWN REGULATION; DRUG EFFECT; DRUG SCREENING; FEMALE; GENETIC TRANSFECTION; GENETICS; HUMAN; LEUKEMIA CELL LINE; LYMPHOMA; MOUSE; ONCOGENE MYC; PATHOLOGY; PHYSIOLOGY; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BRYOSTATINS; CELL GROWTH PROCESSES; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DOWN-REGULATION; FEMALE; GENES, MYC; HUMANS; JURKAT CELLS; LYMPHOMA; MICE; MODELS, BIOLOGICAL; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863224510     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.438     Document Type: Article

References (51)

1. Pettit GR, Herald CL, Doubek DL, Herald DL, Arnold E, Clardy J. Isolation and structure of bryostatin 1. J Am Chem Soc 1982; 104: 6846-8.
2. Hale KJ, Hummersone MG, Manaviazar S, Frigerio M. The chemistry and biology of the bryostatin antitumour macrolides. Nat Prod Rep 2002; 19: 413-53.
3. Wender PA, Baryza JL, Hilinski MK, Horan JC, Kan C, Verma VA. Beyond natural products: synthetic analogues of bryostatin 1. In: Huang Z, editor. Drug discovery research: new frontiers in the post-genomic era. Hoboken, NJ: Wiley-VCH; 2007. p. 127-62.
4. Schrier A, Loy B, Wender PA. Translating nature's library: the bryostatins and function-oriented synthesis. Israel J Chem 2011; 51: 453-72.
5. Shaha SP, Tomic J, Shi Y, Pham T, Mero P, White D, He L, Baryza JL, Wender PA, Booth JW, Spaner DE. Prolonging microtubule dysruption enhances the immunogenicity of chronic lymphocytic leukaemia cells. Clin Exp Immunol 2009; 158: 186-98.
6. Sun MK, Alkon DL. Dual effects of bryostatin-1 on spatial memory and depression. Eur J Pharm 2005; 512: 43-51.
7. Sun MK, Hongpaisan J, Nelson TJ, Alkon DL. Poststroke neuronal rescue and synaptogenesis mediated in vivo by protein kinase C in adult brains. Proc Natl Acad Sci USA 2008; 105: 13620-5.
8. Hongpaisan J, Sun MK, Alkon DL. PKC epsilon activation prevents synaptic loss, Abeta elevation, and cognitive deficits in Alzheimer's disease transgenic mice. J Neurosci 2011; 31: 630-43.
9. Coiras M, Lopez-Huertas MR, Perez-Olmeda M, Alcami J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol 2009; 7: 798-812.
10. Mehla R, Bivalkar-Mehla S, Zhang R, Handy I, Albrecht H, Giri S, Nagarkatti M, Chauhan A. Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS ONE 2010; 5: e11160.
11. Kortmansky J, Schwartz GK. Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest 2003; 21: 924-36.
12. Ku GY, Ilson DH, Schwartz LH, Capanu M, O'Reilly E, Shah MA, Kelsen DP, Schwartz GK. Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer Chemother Pharmacol 2008; 62: 875-80.
13. Barr PM, Lazarus HM, Cooper BW, Schluchter MD, Panneerselvam A, Jacobberger JW, Hsu JW, Janakiraman N, Simic A, Dowlati A, Remick SC. Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant. Am J Hematol 2009; 84: 484-87.
14. Varterasian ML, Mohammad RM, Eilender DS, Hulburd K, Rodriguez DH, Pemberton PA, Pluda JM, Dan MD, Pettit GR, Chen BD, Al-Katib AM. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol 1998; 16: 56-62.
15. Trindade-Silva AE, Lim-Fong GE, Sharp KH, Haygood MG. Bryostatins: biological context and biotechnological prospects. Curr Opin Biotechnol 2010; 21: 834-42.
16. Kageyama M, Tamura T, Nantz MH, Roberts JC, Somfai P, Whritenour DC, Masamune S. Synthesis of bryostatin 7. J Am Chem Soc 1990; 112: 7407-8.
17. Evans DA, Carter PH, Carreira EM, Charette AB, Prunet JA, Lautens M. Total synthesis of bryostatin 2. J Am Chem Soc 1999; 121: 7540-52.
18. Ohmori K, Ogawa Y, Obitsu T, Ishikawa Y, Nishiyama S, Yamamura S. Total Synthesis of Bryostatin 3. Angew Chem Int Ed 2000; 39: 2290-4.
19. Manaviazar S, Frigerio M, Bhatia GS, Hummersone MG, Aliev AE, Hale KJ. Enantioselective formal total synthesis of the antitumor macrolide bryostatin 7. Org Lett 2006; 8: 4477-80.
20. Trost BM, Dong G. Total synthesis of bryostatin 16 using atom-economical and chemoselective approaches. Nature 2008; 456: 485-8.
21. Hale KJ, Manaviazar S. New approaches to the total synthesis of the bryostatin antitumor macrolides. Chem Asian J 2010; 5: 704-54.
22. Keck GE, Poudel YB, Cummins TJ, Rudra A, Covel JA. Total synthesis of bryostatin 1. J Am Chem Soc 2011; 133: 744-7.
23. Lu Y, Woo KS, Krische MJ. TOTAL SYNTHESIS OF BRYOSTATIN 7 VIA C-C BOND-FORMING HYDROGENATION. J Am Chem Soc 2011; 133: 13876-9.
24. Wender PA, Schrier AJ. Total synthesis of bryostatin 9. J Am Chem Soc 2011; 133: 9228-31.
25. Zhang X, Zhang R, Zhao H, Cai H, Gush KA, Kerr RG, Pettit GR, Kraft AS. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. Cancer Res 1996; 56: 802-8.
26. Wender PA, DeChristopher BA, Schrier AJ. Efficient synthetic access to a new family of highly potent bryostatin analogues via a Prins-driven macrocyclization strategy. J Am Chem Soc 2008; 130: 6658-9.
27. Wender PA, Baryza JL, Bennett CE, Bi FC, Brenner SE, Clarke MO, Horan JC, Kan C, Lacôte E, Lippa B, Nell PG, Turner TM. The practical synthesis of a novel and highly potent analogue of bryostatin. J Am Chem Soc 2002; 124: 13648-9.
28. Khan TK, Nelson TJ, Verma VA, Wender PA, Alkon DL. A cellular model of Alzheimer's disease therapeutic efficacy: PKC activation reverses Abeta-induced biomarker abnormality on cultured fibroblasts. Neurobiol Dis 2009; 34: 332-9.
29. Stang SL, Lopez-Campistrous A, Song X, Dower NA, Blumberg PM, Wender PA, Stone JC. A proapoptotic signaling pathway involving RasGRP, Erk, and Bim in B cells. Exp Hematol 2009; 37: 122-34.
30. Stone RM, Sariban E, Pettit GR, Kufe DW. Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood 1988; 72: 208-13.
31. Hu ZB, Gignac SM, Uphoff CC, Quentmeier H, Steube KG, Drexler HG. Induction of differentiation of B-cell leukemia cell lines JVM-2 and EHEB by bryostatin 1. Leuk Lymphoma 1993; 10: 135-42.
32. Steube KG, Grunicke D, Drexler HG. Different biological effects of the two protein kinase C activators bryostatin-1 and TPA on human carcinoma cell lines. Invest New Drugs 1994; 12: 15-23.
33. Vrana JA, Saunders AM, Chellappan SP, Grant S. Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937). Differentiation 1998; 63: 33-42.
34. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992; 89: 5547-51.
35. Furth P, St Onge L, Böger H, Gruss P, Gossen M, Kistner A, Bujard H, Hennighausen L. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc Natl Acad Sci USA 1994; 91: 9302-06.
36. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999; 4: 199-207.
37. Karlsson A, Giuriato S, Tang F, Fung-Weier J, Levan G, Felsher DW. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood 2003; 101: 2797-803.
38. Arvanitis C, Felsher DW. Conditionally MYC: insights from novel transgenic models. Cancer Lett 2005; 226: 95-9.
39. Giuriato S, Ryeom S, Fan AC, Bachireddy P, Lynch RC, Rioth MJ, van Riggelen J, Kopelman AM, Passegué E, Tang F, Folkman J, Felsher DW. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci USA 2006; 103: 16266-71.
40. van Riggelen J, Müller J, Otto T, Beuger V, Yetil A, Choi PS, Kosan C, Möröy T, Felsher DW, Eilers M. The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. Genes Dev 2010; 24:1281-94.
41. Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A, Fan AC, Yang Q, Braunstein L, Crosby E, Ryeom S, Felsher DW. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 2010; 18: 485-98. Erratum in: Cancer Cell 2010; 18: 696.
42. Forshell LP, Li Y, Forshell TZ, Rudelius M, Nilsson L, Keller U, Nilsson J. The direct MYC target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas. Oncotarget 2011; 2: 448-60.
43. Banerjee S, Wang Z, Mohammad M, Sarkar FH, Mohammad RM. Efficacy of selected natural products as therapeutic agents against cancer. J Nat Prod 2008; 71: 492-96.
44. Singh R, Sharma M, Joshi P, Rawat DS. Clinical status of anti-cancer agents derived from marine sources. Anticancer Agents Med Chem 2008; 8: 603-17.
45. Fan AC, Deb-Basu D, Orban MW, Gotlib JR, Natkunam Y, O'Neill R, Padua RA, Xu L, Taketa D, Shirer AE, Beer S, Yee AX, Voehringer DW, Felsher DW. Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Nat Med 2009; 15: 566-71.
46. Seetharam M, Fan AC, Tran M, Xu L, Renschler JP, Felsher DW, Sridhar K, Wilhelm F, Greenberg PL. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leuk Res 2012; 36: 98-103.
47. Newton AC. Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev 2001; 101: 2353-64.
48. Cha E, Graham L, Manjili MH, Bear HD. IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo. Breast Cancer Res Treat 2010; 122: 359-69.
49. Miller CH, Graham L, Bear HD. Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma. BMC Immunol 2010; 11: 54.
50. Kmieciak M, Toor A, Graham L, Bear HD, Manjili MH. Ex vivo expansion of tumor-reactive T cells by means of bryostatin 1/ionomycin and the common gamma chain cytokines formulation. J Vis Exp 2011; 47: pii: 2381.
51. Wender PA, Baryza JL, Brenner SE, DeChristopher BA, Loy BA, Schrier AJ, Verma VA. Function-oriented synthesis: design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity. Proc Natl Acad Sci USA 2011; 108: 6721-26.